A
ANTX
AN2 Therapeutics, Inc.
5.01
+0.13+2.66%After Hours: 5.01 0.00 0.00%19:30 09/28 EDT
OPEN/PREV CLOSE5.39/5.61
TODAY RANGE5.01-5.60
VOL318.21K
MARKET CAP191.32M
52 WEEK RANGE1.000-7.19
AVG VOL (3M)237.85K
% TURNOVER0.77%
TURNOVER--
P/E (TTM)-4.7246
% RANGE10.61%
EPS(TTM)-1.0731
P/E(FORWARD)-5.8953
P/B2.425
BVPS2.091
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP160.23M
SHARES OUTSTANDING37.74M
NEXT EARNINGS11/10-11/16
FREE FLOAT31.60M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Seeking Alpha·09/22 14:43
AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver
Simply Wall St·09/16 11:18
We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
TipRanks·09/03 02:04
Insider Confidence Surges as AN2 Therapeutics Director Adds to Her Stake
TipRanks·08/31 22:05
AN2 Therapeutics presents clinical data supporting development of Epetraborole
Seeking Alpha·08/24 11:44
AN2 Therapeutics appoints biotech veteran Cameron Trenor as CMO
TipRanks·08/11 20:06
AN2 Therapeutics reports Q2 EPS (18c), two estimates (24c)
Seeking Alpha·07/20 14:31
Anterix stock climbs to all-time high as year-to-date gains near 400%
TipRanks·07/20 00:50
AN2 Therapeutics initiated with a Buy at Guggenheim
TipRanks·07/17 12:35
One new option listing on July 17th
TipRanks·06/09 10:45
AN2 Therapeutics Holds 2026 Annual Stockholder Meeting
TipRanks·06/04 21:57
AN2 Therapeutics Advances Chagas Candidate After Positive Trials
Seeking Alpha·06/04 12:21
AN2 rises after early-stage trial data for Chagas disease therapy
TipRanks·06/04 11:18
AN2 Therapeutics reports data from two studies of AN2-502998 in Chagas disease
TipRanks·05/14 10:33
AN2 Therapeutics upgraded to Outperform from Market Perform at Leerink
Same Industry
Name/Symbol
Change%
Price